Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$42.28 USD
-1.48 (-3.38%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $42.27 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Celldex Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 2 | 5 | 7 | 4 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 7 | 2 | 5 | 7 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | 161 | 118 | 76 | 71 | 59 |
Income After Depreciation & Amortization | -155 | -115 | -71 | -63 | -55 |
Non-Operating Income | 13 | 3 | 1 | 2 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -141 | -112 | -71 | -61 | -51 |
Income Taxes | 0 | 0 | 0 | -1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -141 | -112 | -71 | -60 | -51 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -141 | -112 | -71 | -60 | -51 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -158 | -111 | -71 | -60 | -51 |
Depreciation & Amortization (Cash Flow) | -3 | 4 | 0 | 3 | 4 |
Income After Depreciation & Amortization | -155 | -115 | -71 | -63 | -55 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 48.45 | 46.89 | 42.87 | 29.64 | 14.51 |
Diluted EPS Before Non-Recurring Items | -2.66 | -2.23 | -1.58 | -1.80 | -3.28 |
Diluted Net EPS (GAAP) | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 |
Fiscal Year end for Celldex Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 2.50 | 0.16 | 4.13 | 1.52 | 0.27 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 2.50 | 0.16 | 4.13 | 1.52 | 0.27 |
SG&A, R&D, and Dept/Amort Expenses | 48.82 | 40.76 | 39.26 | 42.76 | 33.47 |
Income After SG&A, R&D, and Dept/Amort Expenses | -46.32 | -40.60 | -35.13 | -41.24 | -33.20 |
Non-Operating Income | 10.48 | 7.80 | 4.32 | 2.98 | 2.70 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -35.84 | -32.81 | -43.31 | -38.26 | -30.50 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -35.84 | -32.81 | -43.31 | -38.26 | -30.50 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -35.84 | -32.81 | -43.31 | -38.26 | -30.50 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 66.02 | 58.87 | 52.03 | 47.26 | 47.25 |
Diluted EPS Before Non-Recurring Items | -0.54 | -0.56 | -0.57 | -0.81 | -0.65 |
Diluted Net EPS (GAAP) | -0.54 | -0.56 | -0.84 | -0.81 | -0.65 |